Skip to main content
Press

OsteoStrong® Study Accepted for Publication in The Journal of Clinical Endocrinology & Metabolism (JCEM)

PR Newswire - February 12, 2025

Breakthrough Research Confirms Efficacy of OsteoStrong’s Low-Impact, High-Intensity Osteogenic Loading in Postmenopausal Osteoporosis

HOUSTON, Feb. 12, 2025 /PRNewswire/ — OsteoStrong®, the global leader in osteogenic loading technology for bone health, proudly announces that a groundbreaking study on its proprietary system has been accepted for publication in The Journal of Clinical Endocrinology & Metabolism (JCEM). The study, titled Effective Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis, was conducted by leading researchers Nektaria Papadopoulou-Marketou, Anna Papageorgiou, Nikolaos Marketos, Panagiotis Tsiamyrtzis, Georgios Vavetsis, and George P. Chrousos. This milestone underscores the significant role OsteoStrong® plays in improving bone health and reducing osteoporosis-related risks in postmenopausal women.

Key Findings of the Study

The study evaluated the effectiveness of OsteoStrong®’s intervention in 147 postmenopausal women diagnosed with osteoporosis. Participants were divided into two groups: one receiving the OsteoStrong® intervention and another control group without the intervention. Key results include:

  • Increased Bone Mineral Density (BMD): Statistically significant increases in BMD were observed in the lumbar spine (L1-L4), right and left femoral neck, and total femur in participants utilizing OsteoStrong®.
  • Enhanced Trabecular Bone Score (TBS): OsteoStrong® intervention improved TBS, indicating better bone microarchitecture and reduced fracture risk.
  • Synergistic Effect with Antiresorptive Therapy: The study found that OsteoStrong® enhanced the effectiveness of antiresorptive medications, further boosting bone density improvements.
  • Non-Medication Benefits: Even participants who were not on antiresorptive medications showed significant improvements in bone density.

“These findings reinforce what we have seen anecdotally for years—OsteoStrong®’s unique approach to osteogenic loading significantly improves bone health,” said Kyle Zagrodzky, CEO and Founder of OsteoStrong®. “The acceptance of this research in a prestigious, peer-reviewed medical journal like JCEM is a monumental step in validating OsteoStrong® as a science-backed solution for osteoporosis management.”

A Major Milestone in Osteoporosis Care

Osteoporosis, a condition affecting millions worldwide, leads to reduced bone mineral density and an increased risk of fractures. Traditional treatments primarily rely on medication, but OsteoStrong® provides a revolutionary, non-pharmaceutical alternative that enhances skeletal strength in just one 10-minute session per week.

With JCEM’s publication of this study, OsteoStrong® solidifies its position at the forefront of osteoporosis intervention. The research not only highlights OsteoStrong® as an effective standalone therapy but also showcases its potential to work synergistically with conventional treatments, offering patients a comprehensive path to stronger bones and better health.

About OsteoStrong®

OsteoStrong® is a science-backed, technology-driven system designed to improve bone density, strength, and overall skeletal health. With locations worldwide, OsteoStrong® helps people of all ages build stronger bones in a safe, efficient, and drug-free manner.